Publications by authors named "Cid M de Mello Vianna"
Cost of lost productivity from acute respiratory infections in South America.
Rev Panam Salud Publica
April 2023
Objectives: To estimate the burden of permanent productivity losses caused by acute respiratory infections in South American countries in 2019.
Methods: Mortality data from the Global Burden of Disease Study 2019 were analyzed to estimate the burden of disease attributable to acute respiratory infections. An approach based on the human capital method was used to estimate the cost of permanent productivity losses associated with respiratory diseases.
Objective: Overweight and obesity are important contributors to the non-communicable disease burden. The consumption of sugar-sweetened beverages (SSBs) has been associated with an increased risk of type 2 diabetes mellitus (T2DM), cardiovascular disease, cancer and other conditions. The objective of this study was to estimate the burden of disease attributable to the consumption of SSBs and the costs to the healthcare systems in Argentina, Brazil, El Salvador, and Trinidad and Tobago.
View Article and Find Full Text PDFIntroduction: Respiratory diseases (RD) are an important public health problem. Their burden has not been comprehensively evaluated in South America (SA). This study describes the burden of acute respiratory infections (ARIs) in SA in 2019.
View Article and Find Full Text PDFArticle Synopsis
- - The study evaluates the cost-effectiveness of varenicline compared to other smoking cessation methods in Brazil, using a model to analyze lifetime costs and health benefits for smokers attempting to quit.
- - Various alternatives were assessed, including cognitive behavioral therapy, varenicline, bupropion, and different nicotine replacement therapies, with the analysis considering different age and sex groups.
- - Results showed that while varenicline was effective, it was more expensive and ultimately dominated by combined nicotine replacement therapy, which proved to be the most cost-effective option.
Background: The objective of this paper is to analyze the prices of biological drugs in the treatment of Rheumatoid Arthritis (RA) in three Latin American countries (Brazil, Colombia and Mexico), as well as in Spain and the United States of America (US), from the point of market entry of biosimilars.
Methods: We analyzed products authorized for commercialization in the last 20 years, in Brazil, Colombia, and Mexico, comparing them to the United States of America (USA) and Spain. For this analysis, we sought the prices and registries of drugs marketed between 1999 and October 1, 2019, in the regulatory agencies' databases.
Refractory secondary hyperparathyroidism in waiting list for parathyroidectomy: who we should operate first in a quaternary hospital in Brazil regarding survival.
Ren Fail
November 2019
Background: Few centers in Brazil perform parathyroidectomy (PTX) for recalcitrant secondary hyperparathyroidism (SHPT) generating a long queue. There is little data regarding prioritize criteria besides chronological order and survival.
Objectives: To determine the difference of clinical and laboratory factors between PTX patients and those who remained in the line despite the need for surgery and their survival.